FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Opioid Treatment Devices Study Guidance

[ Price : $8.95]

FDA publishes a guidance recommending principles for use in pivotal clinical studies to demonstrate the safety and effectiveness o...

Kazia Touts Glioblastoma Drug Trial Results

[ Price : $8.95]

Kazia Therapeutics says it will meet with FDA about a potential accelerated approval pathway for its glioblastoma drug paxalisib f...

Workshop on AI in Drug/Biologic Development

[ Price : $8.95]

Federal Register notice: FDA announces an 8/6 public workshop entitled Artificial Intelligence (AI) in Drug & Biological Product D...

Panel to Review Niemann-Pick Disease NDA

[ Price : $8.95]

Federal Register: FDA schedules an 8/2 advisory committee meeting to discuss a Zevra Denmark A/S NDA for arimoclomol, indicated fo...

FDA Clears ImmersiveAR for OR Use

[ Price : $8.95]

FDA clears ImmersiveTouchs ImmersiveAR virtual and augmented reality operating room platform.

CBER Staff Guide on IND Processing, Review

[ Price : $8.95]

CBER issues a standard operating policy and procedure staff guide on administrative processing and review management procedures fo...

Change Device Enforcement Guide: AdvaMedDx

[ Price : $8.95]

AdvaMedDx calls for two substantive changes to an FDA draft guidance on the enforcement policy for certain in vitro diagnostic dev...

Orphan Status for Green Tea Extract in Pouchitis

[ Price : $8.95]

FDA grants PharmasstX an orphan drug designation for epigallocatechin gallate, a green tea extract for treating inflammatory bowel...

30 1st Quarter Serious Risk Signals

[ Price : $8.95]

FDA posts 30 signals of serious risks/new safety information identified by the FAERS in the first quarter of 2024 and is evaluatin...

FDA OKs Cordis Vascular Closure Device

[ Price : $8.95]

FDA approves a Cordis PMA for its Mynx Control Venous Vascular Closure Device for use in certain cardiac ablation procedures.